Accordingly, evidence obtained in 40 patients with NSCLC and treated with anti-PD-1/PD-L1 as monotherapy indicated that patients with clinical benefit (13 over 40) had significantly lower levels of circulating IGF1 and tissue IGF1R than patients who did not show clinical benefit [85]. Here, IGF1R is linked to non-small cell lung carcinoma.